See video to learn about the Mode of Action of Galliprant® (grapiprant tablets). To learn more, go to www.galliprant.... This video is intended for US audience only.
TREAT CANINE OSTEOARTHRITIS (OA) FROM ITS EARLIEST DIAGNOSED STAGES
Galliprant is a first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID. It specifically targets the EP4 receptor, the primary mediator of canine OA pain and inflammation.¹ Treatment can be started in dogs as early as 9 months of age.
• Galliprant does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions¹,²
• It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation¹
1. Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. 2016. "Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation." Vet. Med. Sci. 2: 3-9.
2. Rausch-Derra, LC, Huebner, M, and Rhodes, L. 2015. “Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs.” AJVR. 76.10: 853-859.
INDICATION
Galliprant is an NSAID indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
IMPORTANT SAFETY INFORMATION
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied.The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see the product insert for full prescribing information. bit.ly/2XdSHuU
Galliprant, Elanco and the diagnal bar logo are trademarks of Elanco or its affiliates. ©2021 Elanco or its affiliates. PM-US-21-3193
Негізгі бет Galliprant® (grapiprant tablets) Mode of Action
Пікірлер